TICKERNERD
Menu
ENVBENVBHealthcare · Biotechnology

ENVB Stock Forecast: Enveric Biosciences, Inc. Price Predictions for 2026-2027

Last close, 15 Sept 2026
$1.46
−1.35% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 14 Sept 2026 — in the weakest quartile.

Market cap
$6.6M
Ticker Nerd rank
17 / 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$3.0M
Net income−$3.0M
Free cash flow−$2.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.8%
1M
−4.9%
YTD
−59.8%
1Y
−87.1%
From 52W high
−87.1%
From 52W low
+15.0%
$1
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ENVB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Enveric Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
17 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Growth
64
Accruals
51
Revisions
25
Momentum
25
Issuance
23
Volatility
16
Quality
14
Value
5

Size (94): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ENVB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENVB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$2$4$6$8$10$12Oct 25Jan 26Apr 26Jul 26ENVB

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Mar 2025HC Wainwright & Co.ReiteratesBuy$10
30 Jan 2024HC Wainwright & Co.InitiatesBuy—
1 June 2022Alliance Global PartnersInitiatesBuy$1.25
8 Mar 2022Aegis CapitalDowngradeHold$7.00 → $0.20
8 July 2021Aegis CapitalInitiatesBuy—
28 June 2021Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENVB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ENVB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Sept 2026, Enveric Biosciences, Inc. returned −87.1% against +16.4% for the S&P 500, dividends included.

ENVB vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26ENVBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ENVB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Enveric Biosciences, Inc. (ENVB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
—
Price / book
0.7×

Cheaper than 81% of US stocks

EV / EBITDA
0.2×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−170.0%

Higher than 8% of US stocks

Return on assets
−87.3%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Enveric Biosciences, Inc. (ENVB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Enveric Biosciences, Inc. has a market value of $6.6M and an enterprise value of −$1.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$8.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$8.6M.

  • Shares outstanding: 3.9M.

  • Trailing P/E: 0.0×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Enveric Biosciences, Inc. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

ENVB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ENVBEnveric Biosciences, Inc.$6.6M
17
CLGNCollPlant Biotechnologies Ltd.$6.6M
34
AIMAIM ImmunoTech, Inc.$6.8M
18
ERNAErnexa Therapeutics, Inc.$7.0M
37
CURXCuranex Pharmaceuticals, Inc.$7.0M
6
KAPAKairos Pharma Ltd.$6.2M
40
CDIOCardio Diagnostics Holdings, Inc.$6.1M
20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Enveric Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ENVB news & analysis

Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Business Wire · 15 Sept 2026positive

Enveric Biosciences announced it received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering novel compounds within its EVM401 Series of drug candidates. The EVM401 Series comprises proprietary, non-hallucinogenic mescaline derivatives.

Why it matters — A U.S. patent allowance strengthens Enveric's intellectual property protection for its next-generation neuroplastogenic drug candidates in the EVM401 Series.

Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

Business Wire · 1 Sept 2026neutral

Enveric Biosciences announced that its CEO, Joseph Tucker, Ph.D., will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, in New York City. The presentation will be prerecorded.

Why it matters — The conference appearance offers Enveric a platform to present its neuroplastogenic therapeutic programs to the investment community.

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Business Wire · 14 Aug 2026positive

Enveric Biosciences reported its financial results for the second quarter ended June 30, 2026, and provided a comprehensive corporate update. The company's CEO highlighted important progress made during the quarter on activities supporting its planned first-in-human clinical trial of its next-generation neuroplastogenic small molecules.

Why it matters — An Enveric watcher would care because the corporate update signals continued advancement of the company's pipeline toward a key first-in-human clinical milestone.

Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate

Benzinga · 5 Aug 2026positive

Enveric Biosciences announced new preclinical data confirming that its lead psychiatric candidate, EB-003, maintains a non-hallucinogenic profile.

Why it matters — The data strengthens the differentiation of Enveric's lead candidate, which could be important for investors tracking its progress toward potential psychiatric treatments without hallucinogenic side effects.

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Business Wire · 5 Aug 2026positive

Enveric Biosciences announced new preclinical data from testing its lead candidate EB-003 using a GloSensor cAMP assay, which the company says supports evidence that the drug has a non-hallucinogenic profile.

Why it matters — For ENVB watchers, this data strengthens the case for EB-003 as a potential treatment for psychiatric disorders without the hallucinogenic side effects associated with other psychedelic-derived therapies.

FAQ

Frequently asked questions about ENVB stock

Is ENVB stock a buy right now?

Of the 1 analysts covering Enveric Biosciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enveric Biosciences, Inc. 17 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ENVB?

As at 14 Sept 2026, Enveric Biosciences, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

What is the ENVB stock forecast for 2030?

No analyst covering Enveric Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENVB are extrapolating price history, which says nothing about the business.

How has ENVB stock performed over the past year?

Enveric Biosciences, Inc. returned -87.1% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Enveric Biosciences, Inc. do?

Enveric Biosciences Inc. is a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders.

What is the latest news on ENVB?

The most recent item we track (Business Wire, 15 Sept 2026): "Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series". Enveric Biosciences announced it received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering novel compounds within its EVM401 Series of drug candidates. The EVM401 Series comprises proprietary, non-hallucinogenic mescaline derivatives.

Company

About Enveric Biosciences, Inc.

Enveric Biosciences Inc. is a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. The company’s current pipeline centers on novel compounds designed to promote neuroplasticity while avoiding hallucinogenic effects, with a particular emphasis on depression, anxiety, and addiction-related conditions. Its lead program, EB-003, is being developed as a next-generation therapeutic candidate, and the broader research platform includes proprietary chemical libraries and additional preclinical assets aimed at mental health indications. Enveric Biosciences works at the intersection of neuroscience, medicinal chemistry, and drug discovery, positioning itself within the evolving field of psychedelic-inspired and neuropsychiatric medicine. The company is headquartered in Cambridge, Massachusetts.

CEO Dr. Joseph Edward Tucker Ph.D. · 5 employees · United States · https://www.enveric.com